跳至主要内容
临床试验/TCTR20190607002
TCTR20190607002已完成未知

Incidence, risk and risk factors for acute kidney injury associated with the use of indomethacin injection in neonatal patent ductus arteriosus: a 15-Year experience

Department of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Prince of Songkla University0 个研究点目标入组 205 人开始时间: 2019年6月7日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
205

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
0 Days 至 28 Days(—)
性别
All

入选标准

  • -neonatal patients who were admitted to the NICU between January 2003 and December 2018. Exposed group includes neonatal patients diagnosed with PDA who receives INDO for closure of DA. All diagnoses were recorded according to the International Classification of Diseases 10th revision (ICD-10). (ICD-10 code Q25.0). The non-exposed group includes neonatal patients who were diagnosed with PDA or not and without INDO exposure, matched (1:1) with gestational age and birth weight to the exposed group. The echocardiographic test result, the gold standard method, was used for confirmed diagnosis of PDA among neonatal patients in both exposed and non-exposed groups. However, the echocardiographic test was not performed for confirmation of all PDA closure among neonatal patients. The clinical evidence of ductal closure was used for confirmation of PDA closure. In case the closure of PDA was doubted, the echocardiographic test would be performed for PDA closure confirmation. The criteria for diagnosis of a hemodynamically significant PDA were ductal size >1.5 mm, left atrial to aortic (LA:AO) ratio > 1, and left-to right shunting of blood.46
  • -neonatal patients with availability of baseline SCr concentrations prior to the study entry

排除标准

  • -all neonates diagnosed prior to the study entry with congenital renal anomalies, including, renal artery stenosis (ICD-10 code Q27.1, Q Q27.2), arteriovenous malformation of renal vessel (ICD-10 code Q27.34), dysplasia/hypoplasia (ICD-10 code Q60.3, Q60.4), cystic renal diseases (ICD-10 code Q61.00, Q61.01, Q61.11-Q61.3), other specified congenital malformations of kidney (ICD-10 code Q63.8) and congenital renal failure (ICD-10 code Q96.0).
  • -all neonates diagnosed prior to the study entry with congenital heart anomalies, including, congenital malformation of heart (ICD-10 code Q24.9), congenital heart block (ICD-10 code Q24.6), and other specified congenital malformations of heart (ICD-10 code Q24.8).
  • -all neonates receiving NSAIDs other than INDO will be excluded.

研究者

发起方
Department of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Prince of Songkla University

相似试验